The lawsuit, spearheaded by the Rosen Law Firm, alleges that Beta Bionics provided materially false information to investors about its iLet Bionic Pancreas system. While the company publicly downplayed regulatory concerns, the complaint asserts that the FDA had identified significant malfunctions, including instances where the device administered dangerously high insulin doses. These defects allegedly triggered thousands of complaints and numerous life-threatening hypoglycemic events, contradicting the firm's claims that FDA feedback was benign.

Plaintiffs contend that Beta Bionics failed to implement necessary corrective measures, ultimately causing financial harm to shareholders once the reality of the device's performance reached the market. Investors seeking to participate in the class action or serve as lead counsel representatives must contact the firm before the November deadline. No class has been certified at this time, meaning investors retain the right to select their own counsel or remain absent class members without forfeiting potential future recoveries.